China’s EOC raises $32M to build on crop of harvested cancer drugs

CEO Xiaoming Zou has more licensing deals in his sights.

Shanghai-based biotech EOC Pharma has raised $32 million from Chinese investors to help it bring a series of cancer drugs to market.

The second-round funding will also allow the company—which has built its business by in-licensing externally developed cancer drugs and developing for the Chinese market—to bulk up its pipeline with additional drug candidates, according to founder and chief executive Xiaoming Zou.

The investment will help “position EOC to successfully leverage the improved clinical and regulatory environment and rapidly growing healthcare market in China,” he said.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

EOC Pharma spun out of China’s Eddingpharm in 2015, and Zou still serves as a director of the parent company, having been chief business officer there. He previously also held senior roles at Amgen and GlaxoSmithKline.

The startup currently has six candidates in early- to midstage clinical development, including oral VEGFR2/3 inhibitor telatinib for gastric cancer—originally developed by Bayer—which it licensed from ACT Biotech in 2014 along with two other early-stage candidates, ACTB1003 (an FGFR/VEGFR2 inhibitor) and ACTB1010 (an aurora kinase inhibitor) in 2014.

Telatinib is due to start phase 3 testing in China next year, along with HDAC inhibitor entinostat for breast cancer, which it licenses from Syndax Pharma. Its pipeline also features anti-LAG-3 drug IMP321 (eftilagimod alpha), an immuno-oncology candidate licensed from Austrian biotech Prima Biomed in 2013, and a RANKL-targeting drug from Ablynx.

The fundraising was led by Taikang Industry Development Fund, and Sequoia China, EOC’s series A lead investor, and H&Q Asia Pacific also took part.

“Investment from these top funds underscores the confidence in our strategy to advance differentiated, globally developed oncology products that can transform patients’ lives,” said Zou.

According to BMI Research, China’s pharma market reached a value of $108 billion last year, a 10% increase driven by large and expanding population, increasing burden of chronic diseases and ongoing regulatory reforms that are reshaping the country's drugs market.

Last month, local news sources reported that the Chinese authorities are revamping the approval system for medicines and medical devices to speed up access to new therapies.